Blog
RSS FeedPosted by Michael Wonder on 03 Mar 2023
ABPI response to Government Statutory Scheme rise
2 March 2023 - The Government has confirmed plans to raise the revenue clawback rate paid by pharmaceutical firms subject ...
Posted by Michael Wonder on 02 Mar 2023
FDA and FTC collaborate to advance competition in the biologic marketplace
2 March 2023 - In 2021 alone, the US spent $256 billion on biologics. Although biologics comprise approximately 3% of prescriptions ...
Posted by Michael Wonder on 01 Mar 2023
A review of patient reported outcome considerations in Oncologic Drugs Advisory Committee meetings (2016-2021)
28 February 2023 - The purpose of this project was to gain insight into the role of patient reported outcome data ...
Posted by Michael Wonder on 01 Mar 2023
The drug prices review board was once a solution. It’s now a problem.
1 March 2023 - Anti-drug company activists are repeating ill-informed myths about controlling drug prices in Canada. ...
Posted by Michael Wonder on 28 Feb 2023
Drugs likely subject to Medicare negotiation (2026-2028)
28 February 2023 - In 2026-2028, we estimate that Medicare will negotiate prices for 38 Medicare Part D drugs and 2 ...
Posted by Michael Wonder on 27 Feb 2023
Areteia Therapeutics granted ILAP designation from UK MHRA for oral dexpramipexole for eosinophilic asthma
23 February 2023 - Areteia Therapeutics today announced that the UK’s MHRA has granted an Innovation Passport under the Innovative Licensing ...
Posted by Michael Wonder on 27 Feb 2023
For Cytokinetics, an FDA rejection of its heart drug would help, not hinder
27 February 2023 - Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. ...
Posted by Michael Wonder on 25 Feb 2023
AI developers battle with FDA, what’s next with Amazon and One Medical, & protecting wearables data
23 February 2023 - Health tech companies are in a tizzy. After years of letting companies roll out software tools to ...
Posted by Michael Wonder on 24 Feb 2023
Member of Canada’s drug pricing regulator quits over ‘lack of support’ for medicine cost reforms
23 February 2023 - A member of the Patented Medicine Prices Review Board, Canada’s drug pricing regulator, has resigned over ...
Posted by Michael Wonder on 23 Feb 2023
FDA continues important work to advance medical products for patients with rare diseases
23 February 2023 - Patients with rare diseases are experts in their health condition. They provide a unique perspective, and ...
Posted by Michael Wonder on 21 Feb 2023
$130,000 a year for medicine is outrageous. But I blame the Government, not drug makers.
21 February 2023 - I don't blame President Biden for pursuing price controls. They are popular. Yet popularity does not ...
Posted by Michael Wonder on 21 Feb 2023
The FDA returns to its bad habits
20 February 2023 - The agency may nix a new treatment for a debilitating orphan disease. ...
Posted by Michael Wonder on 20 Feb 2023
Azafaros receives additional regulatory designations for AZ-3102 from FDA, EMA and MHRA
20 February 2023 - Azafaros today announced its progress in on-going interactions with health authorities regarding its lead asset, AZ-3102. ...
Posted by Michael Wonder on 20 Feb 2023
US to select 10 costliest drugs for Medicare pricing negotiation
18 February 2023 - The US Government will select the 10 costliest prescription medicines to Medicare for negotiating prices with ...
Posted by Michael Wonder on 18 Feb 2023
Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn
17 February 2023 - In the aftermath of the FDA’s Aduhelm debacle, the agency’s neuroscience chief Billy Dunn has another ...